
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.
The Phase 2b clinical study is a multi-center, randomized, dose-ranging, double-blind, parallel group comparison clinical trial.